Source-grounded facts extracted from CNS Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CNS Pharmaceuticals, Inc. issued 9,143,479 shares of warrant to institutional investors for $2.299 per Pre-Funded Warrant.
“pre-funded warrants to purchase 9,143,479 shares of the Common Stock (the “Pre-Funded Warrants”) at a purchase price of $2.299 per Pre-Funded Warrant”
CNS Pharmaceuticals, Inc. issued 650,000 shares of common stock to institutional investors for $2.30 per share.
“the Investors purchased in a private placement: (i) 650,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”) at a purchase price of $2.30 per share”
CNS Pharmaceuticals, Inc. entered into Registration Rights Agreement (effective 2026-05-04).
“In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (“Registration Rights Agreement”) and agreed to file a registration statement (the “Registration Statement”) registering the resale of the Common Stock and the Common Stock underlying the Pre-Funded Warrants, within 15 days following the Closing Date”
CNS Pharmaceuticals, Inc. entered into Placement Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the gross proceeds (effective 2026-05-04).
“On May 4, 2026, the Company entered into a placement agency agreement (the “Placement Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”), pursuant to which the Company agreed to pay the Placement Agent an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the sale of the securities in the transaction.”
CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreement with institutional investors valued at $22.5 million (effective 2026-05-04).
“On May 4, 2026, CNS Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Investors purchased in a private placement: (i) 650,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”) at a purchase price of $2.30 per share; and (ii) pre-funded warrants to purchase 9,143,479 shares of the Common Stock (the “Pre-Funded Warrants”) at a purchase price of $2.299 per Pre-Funded Warrant (the “Offering”).”
Michal Fisher was appointed as Independent Director at CNS Pharmaceuticals, Inc..
“On May 4, 2026, the Board agreed to appoint Michal Fisher as an independent member of the Company’s Board.”
Jerzy (George) Gumulka resigned as Director at CNS Pharmaceuticals, Inc..
“On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company’s Board of Directors (the “Board”) . Mr. Gumulka’s resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
CNS Pharmaceuticals, Inc.: Amended articles to increase authorized common stock from 25,000,000 shares to 300,000,000 shares and preferred stock from 416,667 shares to 5,000,000 shares (effective 2025-11-20).
“On November 20, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation (the “Amendment”) with the Secretary of State of the State of Nevada to increase the number of the Company’s authorized shares of common stock from 25,000,000 shares to 300,000,000 shares and to increase the total number of authorized shares of preferred stock from 416,667 shares to 5,000,000 shares.”
CNS Pharmaceuticals, Inc.: Certificate of Change filed to effect a 1-for-12 reverse stock split, proportionally reducing authorized common stock from 300,000,000 to 25,000,000 and preferred stock from 5,000,000 to 416,667 (effective 2025-07-22).
“On July 17, 2025, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a Certificate of Change (the “Certificate of Change”), pursuant to Nevada Revised Statutes 78.209, to effect a one-for-twelve (1-for-12) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”).”
CNS Pharmaceuticals, Inc. reported the first quarter 2024 ended March 31, 2024 results: net income approximately $3.5 million, EPS $(0.34) per diluted share.
“CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.”
CNS Pharmaceuticals, Inc.: On May 2, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to increase authorized shares of common stock from 75,000,000 to 300,000,000, as approved by stockholders at the Annual Meeting on April 30, 2024 (effective 2024-05-02).
“On May 2, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation (the “Amendment”) with the Secretary of State of the State of Nevada to increase the number of the Company’s authorized shares of common stock from 75,000,000 shares to 300,000,000 shares.”
CNS Pharmaceuticals, Inc. shareholders approved Approval of amendments to the Company's 2020 Equity Plan, including an increase in the number of shares of common stock authorized for issuance by 3,500,000 shares.
“CNS Pharmaceuticals, Inc. (the “Company”) held its scheduled 2024 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved amendments to the Company's 2020 Equity Plan (the “2020 Plan”) including an increase in the number of shares of common stock, par value $0.001 per share, authorized for issuance under the 2020 Plan by 3,500,000 shares.”
CNS Pharmaceuticals, Inc. reported the full year ended December 31, 2023 results: net income approximately $18.9 million.
“The net loss for the year ended December 31, 2023 was approximately $18.9 million”
CNS Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 27, 2024, CNS Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq Listing Rule 58”
CNS Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)).
“February 14, 2024, the Staff notified the Company that it had not complied with the Listing Rule and as such did not meet the terms of the extension. The Staff letter stated that unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), the Company would be subject to delisting. Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In that regard, th”
CNS Pharmaceuticals, Inc. amended Warrant Amendment (effective 2024-01-29).
“anuary 29, 2024, the Company entered into a warrant amendment agreement (the “Warrant Amendment”) pursuant to which the Company”
CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors (effective 2024-01-29).
“the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors that participated in the offering”
CNS Pharmaceuticals, Inc. entered into Placement Agreement with A.G.P./Alliance Global Partners and Maxim Group LLC valued at $3.7 million (effective 2024-01-29).
“On January 29, 2024, the Company entered into a placement agency agreement with A.G.P./Alliance Global Partners (“AGP”) and Maxim Group LLC (“Maxim” and collectively with AGP, the “Placement Agents”) (the “Placement Agreement”)”
Amy Mahery was appointed as Independent Director at CNS Pharmaceuticals, Inc..
“As previously reported, on January 17, 2024, the Company’s Board of Directors (the “Board”) agreed to appoint Amy Mahery as an independent member of the Company’s Board effective upon the completion of the Company’s financing.”
Amy Mahery was appointed as Director at CNS Pharmaceuticals, Inc..
“On January 17, 2024, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) agreed to appoint Amy Mahery as an independent member of the Company’s Board of Directors effective upon the completion of the Company’s financing.”
CNS Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 15, 2023, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended September 30, 2023 and recent operational highlights.”
CNS Pharmaceuticals, Inc. entered into Inducement Letter with a holder of certain existing warrants valued at approximately $2.4 million (effective 2023-10-16).
“On October 16, 2023, CNS Pharmaceuticals, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter") with a holder of certain existing warrants (“Holder") to receive new warrants to purchase up to a number of shares of common stock equal to 200% (the “Inducement Warrants") of the number of warrant shares issued pursuant to the exercise of such certain existing warrants to purchase shares of common stock (the “Existing Warrants") pursuant to which the Holder agreed to exercise for cash their Existing Warrants to purchase up to 1,878,000 shares of the Company’s common stock, at a Reduced Exercise Price (as defined below), in exchange for the Company’s agreement to issue the Inducement Warrants to purchase up to 3,756,000 shares of the Company’s common stock (the “Inducement Warrant Shares").”
CNS Pharmaceuticals, Inc. shareholders approved To approve amendments to the Company’s 2020 Stock Plan including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan at the 2023-09-14 meeting.
“Proposal 3. To approve amendments to the Company’s 2020 Stock Plan (the “2020 Plan”) including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan – The Company’s stockholders approved an amendment to the 2020 Plan to increase the number of shares of common stock authorized for issuance under the 2020 Plan by 745,800 shares and to modify the maximum annual limits on awards issuable under the 2020 Plan, by the following vote:”
CNS Pharmaceuticals, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-09-14 meeting.
“Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm - The Company's stockholders ratified the appointment of MaloneBailey, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, by the following vote:”
CNS Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-09-14 meeting.
“Proposal 1. Election of Directors - The Company’s stockholders elected John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Andrzej Andraczke, Carl Evans, Faith Charles and Bettina Cockroft to serve until the 2024 Annual Meeting of Stockholders, or until their successors are duly elected and qualified, by the following vote.”
CNS Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 17, 2023, CNS Pharmaceuticals, Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does”
CNS Pharmaceuticals, Inc.: Reduced quorum requirement from majority to one-third of shares outstanding; specified vote standard for stockholder actions; eliminated stockholder action by written consent; added director removal provision requiring two-thirds vote; updated remote meeting, director meeting, and officer provisions (effective 2023-08-11).
“On August 11, 2023, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) adopted the Amended and Restated Bylaws of CNS Pharmaceuticals, Inc. (as amended and restated, the “Bylaws”), effective on such date.”
CNS Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income The net loss for the three months ended June 30, 2023 was approximately $4.0 million.
“On August 14, 2023, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2023 and recent operational highlights.”
CNS Pharmaceuticals, Inc. reported the quarter ended March 31, 2023 results: net income approximately $4.9 million.
“The net loss for the three months ended March 31, 2023 was approximately $4.9 million compared to approximately $3.2 million for the comparable period in 2022.”
Bettina M. Cockroft was appointed as Independent Director at CNS Pharmaceuticals, Inc..
“On May 3, 2023, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., M.B.A as an independent member of the Company’s Board of Directors effective on such date.”
Faith Charles was appointed as Chairperson of the Board of Directors at CNS Pharmaceuticals, Inc..
“On December 30, 2022, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) appointed Faith Charles as an independent member of the Company’s Board of Directors and as Chairperson of the Board of Directors, effective on such date.”
CNS Pharmaceuticals, Inc. entered into Placement Agreement with H.C. Wainwright & Co., LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (effective 2022-11-30).
“On November 30, 2022, the Company entered into a placement agency agreement with H.C. Wainwright & Co., LLC (“Wainwright”) and Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline” and collectively with Wainright, the “Placement Agents”) (the “Placement Agreement”), pursuant to which the Company has agreed to pay the Placement Agents an aggregate fee equal to 7.0% of the gross proceeds received by the Company from the sale of the securities in the transaction.”
CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreement with an institutional investor valued at approximately $6.0 million.
“On November 30 2022, CNS Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor for the sale by the Company of (i) 147,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,742,764 shares of Common Stock and (iii) warrants to purchase up to an aggregate of 1,889,764 shares of Common Stock (the “Common Warrants” and, collectively with the Pre-Funded Warrants, the “Warrants”), in a public offering.”
CNS Pharmaceuticals, Inc.: Approved amendment to articles of incorporation to effect a 1-for-30 reverse stock split (effective 2022-11-28).
“The Amendment was filed with the Secretary of State of the State of Nevada and the Reverse Stock Split will become effective in accordance with the terms of the Amendment at 4:01 p.m. Eastern Time on November 28, 2022 (the “Effective Time”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.